What is Bioperfectus diagnostic strategy under new SARS-CoV-2 variants?

Company news
2021-06-23

On May 31st, WHO announced simple, easy-to-say labels for SARS-CoV-2 Variants of Interest and Concern. Since the outbreak of SARS-CoV-2, genetic variants of SARS-CoV-2 have been emerging and circulating globally. These variants can be very transmissible and have potential to increase hospitalizations and fatality rates.

In face of SARS-CoV-2 variants, what is our diagnostic strategy?

 

Bioperfectus, as a pioneering infectious disease diagnostic solution provider in the globe, has been studying the characteristics of the SARS-CoV-2 variants and working on developing most effective, efficient and accessible diagnostic solutions to combat COVID-19 pandemic.

 

Under the investigation of Bioperfectus R&D team, we hereby conclude that Bioperfectus COVID-19 Coronavirus Real Time PCR Kit, COVID-19 Coronavirus (ORF1ab/N/E) Real Time PCR Kit and COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit are confirmed to stay effective and free from the impact of the listed SARS-CoV-2 variants below:

 

 

Reference: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14